(lp0
S'Cantor Fitzgerald Reaffirms Neutral Rating for Alkermes Plc  BNB Daily  - Feb 3, 2017 Alkermes Plc logo Cantor Fitzgerald reissued their neutral rating on shares of Alkermes Plc  in a report released on Thursday.'
p1
aS'Alkermes plc  to Present Data on Two-Month Dosing Option of ARISTADA at ... StreetInsider.com - Mar 20, 2017 Alkermes plc  today announced that data for the two-month dosing option of ARISTADA  extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress&nbsp;...'
p2
aS'Analyst Activity  Cowen and Company Reiterates Positive on Alkermes Plc ... Market Exclusive - Mar 21, 2017 The current consensus rating on Alkermes Plc  is Buy  with a consensus target price of $63.90 per share, a potential 7.07% upside.'
p3
aS'Insider Trading Activity Alkermes Plc   Insider Sold 1900 shares ... Market Exclusive - 3 hours ago On 1/16/2014 James Frates, CFO, sold 7,000 with an average share price of $47.40 per share and the total transaction amounting to $331,800.00.'
p4
aS'Alkermes plc  Initiates Phase 3 Gastrointestinal Tolerability Study of ... StreetInsider.com - Mar 16, 2017 Alkermes plc  today announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate  prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis .'
p5
aS'Analyst Activity  Cantor Fitzgerald Reiterates Hold on Alkermes Plc  Market Exclusive - Mar 16, 2017 Today, Cantor Fitzgerald reiterated its Hold rating on Alkermes Plc  with a price target of $51.00. There are 3 hold ratings, 7 buy ratings on the stock.Cantor Fitzgerald Maintains Neutral Rating and $51 PT on Alkermes plc (ALKS ... - StreetInsider.comAlkermes Plc  Stock Rating Reaffirmed by Cantor Fitzgerald - The Cerbat Gem'
p6
aS'Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward Motley Fool - Nov 7, 2016 Alkermes , a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.'
p7
aS"Why Alkermes PLC Skyrocketed Today Motley Fool - Oct 21, 2016 Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.Credit Suisse Bullish on Alkermes Plc  as It Takes a Leap FORWARD - Smarter AnalystAlkermes plc  Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD - StreetInsider.com"
p8
aS"Alkermes Plc  Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 15, 2017 Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today.Alkermes plc  Tops Q4 EPS by 11c - StreetInsider.com"
p9
aS"Alkermes Plc  Given Positive Rating at Cowen and Company Chaffey Breeze - 11 hours ago Cowen and Company reiterated their positive rating on shares of Alkermes Plc  in a research note issued to investors on Tuesday.Stock Returns: Tesaro Inc  is Beating Alkermes plc  - CML NewsTime To Buy These Stocks? Analyst's Take on Alkermes plc  Micron ... - Sherwood Daily"
p10
a.